The INCORRECT Statement is D
Statement D ("Less than 3% of patients require systemic therapy") is definitively INCORRECT. In reality, a substantial proportion of IBD patients require systemic therapy with corticosteroids, immunosuppressants, or biologics during their disease course—far exceeding 3%.
Analysis of Each Statement
Statement A: Presence of Systemic Inflammation - CORRECT
Systemic inflammatory markers (anemia, hypoalbuminemia, elevated CRP/ESR) are legitimate indicators for escalating to systemic therapy. These markers reflect disease severity and activity that extends beyond mild, localized inflammation, warranting more aggressive treatment approaches.
Statement B: Extensive Disease with Deep Ulcers - CORRECT
Endoscopic findings of extensive disease with deep ulceration represent severe mucosal damage requiring systemic therapy. This aligns with the treatment paradigm that endoscopic severity guides therapeutic escalation, as mucosal healing has become a key therapeutic endpoint 1.
Statement C: Failure After 4-7 Days of Conservative Therapy - CORRECT
This timeframe is clinically appropriate for assessing response to initial conservative management (typically 5-ASA therapy or topical treatments). The 2025 British Society of Gastroenterology guidelines indicate that treatment response should be assessed within this window, and failure to respond necessitates escalation 1.
Statement D: Less Than 3% Require Systemic Therapy - INCORRECT
This statement grossly underestimates the proportion of IBD patients requiring systemic therapy. In clinical practice:
- Corticosteroids remain one of the most frequently prescribed medications for IBD management 2
- A significant proportion of patients develop steroid-dependent or steroid-resistant disease, requiring immunosuppressants or biologics 3, 4
- The evolution toward early use of disease-modifying agents (biologics, immunosuppressants) in patients with aggressive disease means systemic therapy is now standard care for moderate-to-severe IBD 4
- The actual percentage requiring systemic therapy is substantially higher—likely 30-50% or more of IBD patients will need these agents at some point
Statement E: Avoiding Chronic Oral Corticosteroids - CORRECT
Corticosteroids are explicitly not recommended for long-term maintenance therapy 1. The 2025 BSG guidelines clearly state that "maintenance therapy should be continued with the agent successful in achieving induction, with the important exception that corticosteroids are not recommended for long-term maintenance" 1. This is due to well-established adverse effects including osteoporosis, metabolic complications, infections, and other steroid-related toxicities 2, 5.
Clinical Pitfall
The 3% figure in statement D may confuse systemic therapy with some other metric (perhaps surgical intervention rates or a specific subset of patients). Do not be misled—systemic therapy is a cornerstone of moderate-to-severe IBD management, not a rare occurrence.